Skip to main content

ACCIONES PARA MEJORAR LA CALIDAD DE VIDA DE LOS PACIENTES DE MCARDLE: UNA APROXIMACION MULTIDISCIPLINAR

PI19/01313

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. (CIBER)
Execution centre HOSPITAL VALLE DE HEBRON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Second Wind in McArdle Patients: Fitness Matters

  • Salazar-Martínez, Eduardo
  • Valenzuela, Pedro L.
  • Nogales-Gadea, Gisela
  • Pinós Figueras, Tomàs
  • Morán, María
  • Santalla Hernández, Alfredo
Glucogenosis tipo 5; Deficiencia de miofosforilasa; Umbral de ventilación, Glycogenosis type 5; Myophosphorylase deficiency; Ventilatory threshold, Glucogenosi tipus 5; Deficiència de miofosforilasa; Llindar ventilatori, Background: The “second wind” (SW) phenomenon—commonly referring to both an initial period of marked intolerance to dynamic exercise (e.g., brisk walking) that is not followed by perceived improvement and disappearance of previous tachycardia (i.e., the actual “SW”) until 6–10 min has elapsed—is an almost unique feature of McArdle disease that limits adherence to an active lifestyle. In this regard, an increase in the workload eliciting the SW could potentially translate into an improved patients’ exercise tolerance in daily life. We aimed to determine whether aerobic fitness and physical activity (PA) levels are correlated with the minimum workload eliciting the SW in McArdle patients—as well as with the corresponding heart rate value. We also compared the SW variables and aerobic fitness indicators in inactive vs. active patients. Methods: Fifty-four McArdle patients (24 women, mean ± SD age 33 ± 12 years) performed 12-min constant-load and maximum ramp-like cycle-ergometer tests for SW detection and aerobic fitness [peak oxygen uptake (VO2peak) and workload and ventilatory threshold] determination, respectively. They were categorized as physically active/inactive during the prior 6 months (active = reporting ≥150 min/week or ≥75 min/week in moderate or vigorous-intensity aerobic PA, respectively) and were also asked on their self-report of the SW. Results: Both peak and submaximal indicators of aerobic fitness obtained in the ramp tests were significantly correlated with the workload of the SW test, with a particularly strong correlation for the VO2peak and peak workload attained by the patients (both Pearson’s coefficients > 0.70). Twenty (seven women) and 24 patients (18 women) were categorized as physically active and inactive, respectively. Not only the aerobic fitness level [∼18–19% higher values of VO2peak (ml⋅kg–1⋅min–1)] but also the workload of the SW tests was significantly higher in active than in inactive patients. All the inactive patients reported that they experienced the SW during walking/brisk walking in daily life, whereas active patients only reported experiencing this phenomenon during more strenuous activities (very brisk walking/jogging and bicycling). Conclusion: A higher aerobic fitness and an active lifestyle are associated with a higher workload eliciting the so-called SW phenomenon in patients with McArdle disease, which has a positive impact on their exercise tolerance during daily living., Research by AL, CF-L, GN-G, MM, and TP was funded by the Instituto de Salud Carlos III (ISCIII) and Fondos Feder (grants PI18/00139, PI20/00645, PI18/00713, PI17/00093, and PI19/01313). CF-L and GN-G were supported by Miguel Servet contracts (CP18/00034 and CPII19/00021, respectively) from ISCIII. The funders had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the manuscript for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Growth Factors Do Not Improve Muscle Function in Young or Adult mdx Mice

  • Nielsen, Tue
  • Hornsyld, Tessa Munkeboe
  • Pinós Figueras, Tomàs
  • Hjortkjær, Camilla Brolin
  • Vissing, John
  • Krag, Thomas
Hepatocyte growth factor; Leukemia inhibitory factor; Muscular regeneration, Factor de crecimiento de los hepatocitos; Factor inhibidor de la leucemia; Regeneración muscular, Factor de creixement dels hepatòcits; Factor inhibidor de la leucèmia; Regeneració muscular, Muscular dystrophies constitute a broad group of genetic disorders leading to muscle wasting. We have previously demonstrated that treating a muscular atrophy mouse model with growth factors resulted in increased muscle mass. In the present study, we treated the Duchenne mouse model mdx for 12 weeks with myogenic growth factors peri- and post-onset of muscular degeneration to explore the effects in the oxidative muscle soleus and the glycolytic muscle extensor digitorum longus (EDL). We found no overall beneficial effect in the peri-onset group at the conclusion of the study. In the post-onset group, the functional improvement by means of electrophysiological examinations ex vivo was mostly confined to the soleus. EDL benefitted from the treatment on a molecular level but did not improve functionally. Histopathology revealed signs of inflammation at the end of treatment. In conclusion, the growth factor cocktail failed to improve the mdx on a functional level., This work was supported by grants from the Lundbeck Foundation (Grant No. R140-2013-13370 to J.V. and T.O.K.), Novo Nordisk Foundation (Grant No. 8091 to J.V. and T.O.K.), AP Møller Foundations (Grant No. 13-222 to T.O.K.), Instituto de Salud Carlos III y Fondos FEDER (FIS Project PI19/01313 to T.P.), and Augustinus Foundation (Grant No. 13-4153 to T.O.K.). None of the funding sources had any involvement in the study, data evaluation, or authoring of the manuscript.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Preclinical research in glycogen storage diseases, a comprehensive review of current animal models

  • Almodóvar Payá, Aitana|||0000-0002-1650-2908
  • Villarreal-Salazar, Mónica|||0000-0002-8794-691X
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Nogales, Gisela|||0000-0002-7414-212X
  • Real-Martinez, Alberto|||0000-0002-4703-5142
  • Andreu Périz, Antoni Lluís
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Vissing, John|||0000-0001-6144-8544
  • Krag, Thomas|||0000-0001-9330-668X
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
GSD are a group of disorders characterized by a defect in gene expression of specific enzymes involved in glycogen breakdown or synthesis, commonly resulting in the accumulation of glycogen in various tissues (primarily the liver and skeletal muscle). Several different GSD animal models have been found to naturally present spontaneous mutations and others have been developed and characterized in order to further understand the physiopathology of these diseases and as a useful tool to evaluate potential therapeutic strategies. In the present work we have reviewed a total of 42 different animal models of GSD, including 26 genetically modified mouse models, 15 naturally occurring models (encompassing quails, cats, dogs, sheep, cattle and horses), and one genetically modified zebrafish model. To our knowledge, this is the most complete list of GSD animal models ever reviewed. Importantly, when all these animal models are analyzed together, we can observe some common traits, as well as model specific differences, that would be overlooked if each model was only studied in the context of a given GSD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Preclinical Research in McArdle Disease, A Review of Research Models and Therapeutic Strategies

  • Villarreal-Salazar, Mónica|||0000-0002-8794-691X
  • Brull, Astrid|||0000-0002-3012-451X
  • Nogales, Gisela|||0000-0002-7414-212X
  • Andreu Périz, Antoni Lluís
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Vissing, John|||0000-0001-6144-8544
  • Krag, Thomas|||0000-0001-9330-668X
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
McArdle disease is an autosomal recessive disorder of muscle glycogen metabolism caused by pathogenic mutations in the PYGM gene, which encodes the skeletal muscle-specific isoform of glycogen phosphorylase. Clinical symptoms are mainly characterized by transient acute "crises" of early fatigue, myalgia and contractures, which can be accompanied by rhabdomyolysis. Owing to the difficulty of performing mechanistic studies in patients that often rely on invasive techniques, preclinical models have been used for decades, thereby contributing to gain insight into the pathophysiology and pathobiology of human diseases. In the present work, we describe the existing in vitro and in vivo preclinical models for McArdle disease and review the insights these models have provided. In addition, despite presenting some differences with the typical patient's phenotype, these models allow for a deep study of the different features of the disease while representing a necessary preclinical step to assess the efficacy and safety of possible treatments before they are tested in patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry)

  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Andreu Périz, Antoni Lluís
  • Bruno, Claudio
  • Hadjigeorgiou, Georgios M.
  • Haller, Ronald G.
  • Laforêt, Pascal
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Martinuzzi, Andrea
  • Navarro, Carmen|||0000-0003-4445-8585
  • Oflazer, Piraye
  • Pouget, Jean
  • Quinlivan, Ros
  • Sacconi, Sabrina
  • Scalco, Renata S.
  • Toscano, Antonio
  • Vissing, John|||0000-0001-6144-8544
  • Vorgerd, Matthias
  • Wakelin, Andrew
  • Martí, Ramon A.|||0000-0002-8273-9540
International patient registries are of particular importance for rare disorders, as they may contribute to overcome the lack of knowledge derived from low number of patients and limited awareness of these diseases, and help to learn more about their geographical or population-based specificities, which is relevant for research purposes and for promoting better standards of care and diagnosis. Our objective was to create and implement a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC) and to disseminate the knowledge of these disorders. Teams from nine different countries (United Kingdom, Spain, Italy, France, Germany, Denmark, Greece, Turkey and USA) created a consortium that developed the first European registry dedicated to rare muscle glycogenoses. A work plan was implemented to design the database and platform that constitute the registry, by choosing clinical, genetics and molecular variables of interest, based on experience gained from previous national registries for similar metabolic disorders. Among dissemination activities, several teaching events were organized in different countries, especially those where the consortium considered the awareness of these diseases needs to be promoted among health professionals and patients. EUROMAC represents a step forward in the knowledge of those disorders to which it is dedicated, and will have relevant clinical outcomes at the diagnostic, epidemiological, clinical and research level.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

  • Scalco, Renata S.
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Martinuzzi, Andrea
  • Vavla, Marinela
  • Reni, Gianluigi
  • Toscano, Antonio
  • Musumeci, Olimpia|||0000-0002-9208-1527
  • Voermans, Nicol C.|||0000-0002-5837-7295
  • Kouwenberg, Carlyn V.
  • Laforêt, Pascal
  • San-Millán, Beatriz
  • Vieitez, Irene
  • Siciliano, Gabriele
  • Kühnle, Enrico
  • Trost, Rebeca
  • Sacconi, Sabrina
  • Stemmerik, Mads G.
  • Durmus, Hacer
  • Kierdaszuk, Biruta
  • Wakelin, Andrew
  • Andreu Périz, Antoni Lluís
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Quinlivan, Ros
  • Vissing, John|||0000-0001-6144-8544
The European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC) was launched to register rare muscle glycogenoses in Europe, to facilitate recruitment for research trials and to learn about the phenotypes and disseminate knowledge about the diseases through workshops and websites. A network of twenty full and collaborating partners from eight European countries and the US contributed data on rare muscle glycogenosis in the EUROMAC registry. After approximately 3 years of data collection, the data in the registry was analysed. Of 282 patients with confirmed diagnoses of muscle glycogenosis, 269 had McArdle disease. New phenotypic features of McArdle disease were suggested, including a higher frequency (51.4%) of fixed weakness than reported before, normal CK values in a minority of patients (6.8%), ptosis in 8 patients, body mass index above background population and number of comorbidities with a higher frequency than in the background population (hypothyroidism, coronary heart disease). The EUROMAC project and registry have provided insight into new phenotypic features of McArdle disease and the variety of co-comorbidities affecting people with McArdle disease. This should lead to better management of these disorders in the future, including controlling weight, and preventive screening for thyroid and coronary artery diseases, as well as physical examination with attention on occurrence of ptosis and fixed muscle weakness. Normal serum creatine kinase in a minority of patients stresses the need to not discard a diagnosis of McArdle disease even though creatine kinase is normal and episodes of myoglobinuria are absent.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Growth Factors Do Not Improve Muscle Function in Young or Adult mdx Mice

  • Nielsen, Tue L.
  • Hornsyld, Tessa M.
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Brolin, Camilla
  • Vissing, John|||0000-0001-6144-8544
  • Krag, Thomas|||0000-0001-9330-668X
Muscular dystrophies constitute a broad group of genetic disorders leading to muscle wasting. We have previously demonstrated that treating a muscular atrophy mouse model with growth factors resulted in increased muscle mass. In the present study, we treated the Duchenne mouse model mdx for 12 weeks with myogenic growth factors peri- and post-onset of muscular degeneration to explore the effects in the oxidative muscle soleus and the glycolytic muscle extensor digitorum longus (EDL). We found no overall beneficial effect in the peri-onset group at the conclusion of the study. In the post-onset group, the functional improvement by means of electrophysiological examinations ex vivo was mostly confined to the soleus. EDL benefitted from the treatment on a molecular level but did not improve functionally. Histopathology revealed signs of inflammation at the end of treatment. In conclusion, the growth factor cocktail failed to improve the mdx on a functional level.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Low aerobic capacity in McArdle disease, A role for mitochondrial network impairment?

  • Villarreal-Salazar, Mónica|||0000-0002-8794-691X
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Real-Martinez, Alberto|||0000-0002-4703-5142
  • Nogales, Gisela|||0000-0002-7414-212X
  • Valenzuela, P.L.
  • Fiuza-Luces, Carmen
  • Andreu, A. L.
  • Rodríguez Aguilera, Juan Carlos|||0000-0002-3371-4128
  • Martín, M.A.
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Vissing, John|||0000-0001-6144-8544
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Krag, Thomas|||0000-0001-9330-668X
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
McArdle disease is caused by myophosphorylase deficiency and results in complete inability for muscle glycogen breakdown. A hallmark of this condition is muscle oxidation impairment (e.g., low peak oxygen uptake (VO)), a phenomenon traditionally attributed to reduced glycolytic flux and Krebs cycle anaplerosis. Here we hypothesized an additional role for muscle mitochondrial network alterations associated with massive intracellular glycogen accumulation. We analyzed in depth mitochondrial characteristics-content, biogenesis, ultrastructure-and network integrity in skeletal-muscle from McArdle/control mice and two patients. We also determined VO in patients (both sexes, N = 145) and healthy controls (N = 133). Besides corroborating very poor VO values in patients and impairment in muscle glycolytic flux, we found that, in McArdle muscle: (a) damaged fibers are likely those with a higher mitochondrial and glycogen content, which show major disruption of the three main cytoskeleton components-actin microfilaments, microtubules and intermediate filaments-thereby contributing to mitochondrial network disruption in skeletal muscle fibers; (b) there was an altered subcellular localization of mitochondrial fission/fusion proteins and of the sarcoplasmic reticulum protein calsequestrin-with subsequent alteration in mitochondrial dynamics/function; impairment in mitochondrial content/biogenesis; and (c) several OXPHOS-related complex proteins/activities were also affected. In McArdle disease, severe muscle oxidative capacity impairment could also be explained by a disruption of the mitochondrial network, at least in those fibers with a higher capacity for glycogen accumulation. Our findings might pave the way for future research addressing the potential involvement of mitochondrial network alterations in the pathophysiology of other glycogenoses.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of Potential Muscle Biomarkers in McArdle Disease, Insights from Muscle Proteome Analysis

  • García-Consuegra, Inés
  • Asensio-Peña, Sara|||0000-0002-2048-5899
  • Garrido-Moraga, Rocío|||0000-0002-2856-4399
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Nogales, Gisela|||0000-0002-7414-212X
  • Serrano-Lorenzo, Pablo|||0000-0002-5661-7574
  • Andreu Périz, Antoni Lluís
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Zugaza, José L.|||0000-0002-9000-6398
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Martín, Miguel A.|||0000-0003-4741-772X
Glycogen storage disease type V (GSDV, McArdle disease) is a rare genetic myopathy caused by deficiency of the muscle isoform of glycogen phosphorylase (PYGM). This results in a block in the use of muscle glycogen as an energetic substrate, with subsequent exercise intolerance. The pathobiology of GSDV is still not fully understood, especially with regard to some features such as persistent muscle damage (i.e., even without prior exercise). We aimed at identifying potential muscle protein biomarkers of GSDV by analyzing the muscle proteome and the molecular networks associated with muscle dysfunction in these patients. Muscle biopsies from eight patients and eight healthy controls showing none of the features of McArdle disease, such as frequent contractures and persistent muscle damage, were studied by quantitative protein expression using isobaric tags for relative and absolute quantitation (iTRAQ) followed by artificial neuronal networks (ANNs) and topology analysis. Protein candidate validation was performed by Western blot. Several proteins predominantly involved in the process of muscle contraction and/or calcium homeostasis, such as myosin, sarcoplasmic/endoplasmic reticulum calcium ATPase 1, tropomyosin alpha-1 chain, troponin isoforms, and alpha-actinin-3, showed significantly lower expression levels in the muscle of GSDV patients. These proteins could be potential biomarkers of the persistent muscle damage in the absence of prior exertion reported in GSDV patients. Further studies are needed to elucidate the molecular mechanisms by which PYGM controls the expression of these proteins.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Second Wind in McArdle Patients, Fitness Matters

  • Salazar-Martínez, Eduardo
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Valenzuela, Pedro L.
  • Nogales, Gisela|||0000-0002-7414-212X
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Morán, María|||0000-0001-5408-7189
  • Santos-Lozano, Alejandro
  • Fiuza-Luces, Carmen
  • Lucia, Alejandro|||0000-0002-3025-2060
Background: The "second wind" (SW) phenomenon-commonly referring to both an initial period of marked intolerance to dynamic exercise (e.g., brisk walking) that is not followed by perceived improvement and disappearance of previous tachycardia (i.e., the actual "SW") until 6-10 min has elapsed-is an almost unique feature of McArdle disease that limits adherence to an active lifestyle. In this regard, an increase in the workload eliciting the SW could potentially translate into an improved patients' exercise tolerance in daily life. We aimed to determine whether aerobic fitness and physical activity (PA) levels are correlated with the minimum workload eliciting the SW in McArdle patients-as well as with the corresponding heart rate value. We also compared the SW variables and aerobic fitness indicators in inactive vs. active patients. Methods: Fifty-four McArdle patients (24 women, mean ± SD age 33 ± 12 years) performed 12-min constant-load and maximum ramp-like cycle-ergometer tests for SW detection and aerobic fitness [peak oxygen uptake (VO ) and workload and ventilatory threshold] determination, respectively. They were categorized as physically active/inactive during the prior 6 months (active = reporting ≥150 min/week or ≥75 min/week in moderate or vigorous-intensity aerobic PA, respectively) and were also asked on their self-report of the SW. Results: Both peak and submaximal indicators of aerobic fitness obtained in the ramp tests were significantly correlated with the workload of the SW test, with a particularly strong correlation for the VO and peak workload attained by the patients (both Pearson's coefficients.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Second Wind in McArdle Patients: Fitness Matters

  • Salazar-Martínez, Eduardo
  • Valenzuela, Pedro L.
  • Nogales-Gadea, Gisela
  • Pinós Figueras, Tomàs
  • Morán, María
  • Santalla Hernández, Alfredo
Glucogenosis tipo 5; Deficiencia de miofosforilasa; Umbral de ventilación, Glycogenosis type 5; Myophosphorylase deficiency; Ventilatory threshold, Glucogenosi tipus 5; Deficiència de miofosforilasa; Llindar ventilatori, Background: The “second wind” (SW) phenomenon—commonly referring to both an initial period of marked intolerance to dynamic exercise (e.g., brisk walking) that is not followed by perceived improvement and disappearance of previous tachycardia (i.e., the actual “SW”) until 6–10 min has elapsed—is an almost unique feature of McArdle disease that limits adherence to an active lifestyle. In this regard, an increase in the workload eliciting the SW could potentially translate into an improved patients’ exercise tolerance in daily life. We aimed to determine whether aerobic fitness and physical activity (PA) levels are correlated with the minimum workload eliciting the SW in McArdle patients—as well as with the corresponding heart rate value. We also compared the SW variables and aerobic fitness indicators in inactive vs. active patients. Methods: Fifty-four McArdle patients (24 women, mean ± SD age 33 ± 12 years) performed 12-min constant-load and maximum ramp-like cycle-ergometer tests for SW detection and aerobic fitness [peak oxygen uptake (VO2peak) and workload and ventilatory threshold] determination, respectively. They were categorized as physically active/inactive during the prior 6 months (active = reporting ≥150 min/week or ≥75 min/week in moderate or vigorous-intensity aerobic PA, respectively) and were also asked on their self-report of the SW. Results: Both peak and submaximal indicators of aerobic fitness obtained in the ramp tests were significantly correlated with the workload of the SW test, with a particularly strong correlation for the VO2peak and peak workload attained by the patients (both Pearson’s coefficients > 0.70). Twenty (seven women) and 24 patients (18 women) were categorized as physically active and inactive, respectively. Not only the aerobic fitness level [∼18–19% higher values of VO2peak (ml⋅kg–1⋅min–1)] but also the workload of the SW tests was significantly higher in active than in inactive patients. All the inactive patients reported that they experienced the SW during walking/brisk walking in daily life, whereas active patients only reported experiencing this phenomenon during more strenuous activities (very brisk walking/jogging and bicycling). Conclusion: A higher aerobic fitness and an active lifestyle are associated with a higher workload eliciting the so-called SW phenomenon in patients with McArdle disease, which has a positive impact on their exercise tolerance during daily living., Research by AL, CF-L, GN-G, MM, and TP was funded by the Instituto de Salud Carlos III (ISCIII) and Fondos Feder (grants PI18/00139, PI20/00645, PI18/00713, PI17/00093, and PI19/01313). CF-L and GN-G were supported by Miguel Servet contracts (CP18/00034 and CPII19/00021, respectively) from ISCIII. The funders had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the manuscript for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Growth Factors Do Not Improve Muscle Function in Young or Adult mdx Mice

  • Nielsen, Tue
  • Hornsyld, Tessa Munkeboe
  • Pinós Figueras, Tomàs
  • Hjortkjær, Camilla Brolin
  • Vissing, John
  • Krag, Thomas
Hepatocyte growth factor; Leukemia inhibitory factor; Muscular regeneration, Factor de crecimiento de los hepatocitos; Factor inhibidor de la leucemia; Regeneración muscular, Factor de creixement dels hepatòcits; Factor inhibidor de la leucèmia; Regeneració muscular, Muscular dystrophies constitute a broad group of genetic disorders leading to muscle wasting. We have previously demonstrated that treating a muscular atrophy mouse model with growth factors resulted in increased muscle mass. In the present study, we treated the Duchenne mouse model mdx for 12 weeks with myogenic growth factors peri- and post-onset of muscular degeneration to explore the effects in the oxidative muscle soleus and the glycolytic muscle extensor digitorum longus (EDL). We found no overall beneficial effect in the peri-onset group at the conclusion of the study. In the post-onset group, the functional improvement by means of electrophysiological examinations ex vivo was mostly confined to the soleus. EDL benefitted from the treatment on a molecular level but did not improve functionally. Histopathology revealed signs of inflammation at the end of treatment. In conclusion, the growth factor cocktail failed to improve the mdx on a functional level., This work was supported by grants from the Lundbeck Foundation (Grant No. R140-2013-13370 to J.V. and T.O.K.), Novo Nordisk Foundation (Grant No. 8091 to J.V. and T.O.K.), AP Møller Foundations (Grant No. 13-222 to T.O.K.), Instituto de Salud Carlos III y Fondos FEDER (FIS Project PI19/01313 to T.P.), and Augustinus Foundation (Grant No. 13-4153 to T.O.K.). None of the funding sources had any involvement in the study, data evaluation, or authoring of the manuscript.